Lecozotan

Lecozotan is an investigational drug by Wyeth tested for improvement of cognitive functions of Alzheimer's disease patients.[1] As of June 2008, the first Phase III clinical trial has been completed.[2]

Lecozotan
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC28H30ClN5O3
Molar mass520.021 g/mol g·mol−1
3D model (JSmol)
  (verify)

Method of action

Lecozotan is a competitive, selective 5-HT1A receptor antagonist[3] which enhances the potassium-stimulated release of acetylcholine and glutamate.[4]

References

  1. H. Spreitzer (August 13, 2008). "Neue Wirkstoffe - Lecozotan". Österreichische Apothekerzeitung (in German) (17/2007): 805.
  2. ClinicalTrials
  3. Schlechter, LE; Smith, DL; Rosenzweig-Lipson, S; Sukoff, SJ; Dawson, LA; Marquis, K; Jones, D; Piesla, M; et al. (June 10, 2005). "Lecotozan (SRA-333): A selective serotonin1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and promotes procognitive effects". Journal of Pharmacology and Experimental Therapeutics. 314 (3): 1274–89. arXiv:1506.05421. doi:10.1124/jpet.105.086363. PMID 15951399.
  4. Childers, WE Jr, Harrison, BL, Abou-Gharbia, MA, Raje, S, Parks, V, Pangalos, MN, Schechter, LE (2007). "Lecozotan Hydrochloride". Drugs of the Future. 32 (5): 399–407. doi:10.1358/dof.2007.032.05.1092901.CS1 maint: multiple names: authors list (link)
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.